|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approval_authority
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:casnumber
|
1421370-80-0
|
|
gptkbp:chemical_formula
|
C22 H24 N2 O3 S
|
|
gptkbp:clinical_trial
|
Phase 1
NCT02122913
NCT02576431
NCT03036899
NCT03215511
|
|
gptkbp:composed_by
|
synthetic organic chemistry
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to LOXO-101
|
|
gptkbp:developed_by
|
gptkb:Loxo_Oncology
|
|
gptkbp:discovery
|
high-throughput screening
|
|
gptkbp:discovery_year
|
gptkb:2015
|
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:effective_date
|
2018-11-26
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
LOXO-101
|
|
gptkbp:indication
|
solid tumors
|
|
gptkbp:invention
|
US20160217412 A1
US20160217413 A1
US20160217414 A1
US20160217415 A1
|
|
gptkbp:launch_date
|
gptkb:2018
|
|
gptkbp:lifespan
|
approximately 12 hours
|
|
gptkbp:market_launch
|
gptkb:USA
gptkb:EU
|
|
gptkbp:marketed_as
|
gptkb:Vitrakvi
|
|
gptkbp:mechanism_of_action
|
inhibitor of tropomyosin receptor kinase (TRK)
|
|
gptkbp:patient_population
|
adults
pediatric patients
|
|
gptkbp:research_areas
|
oncology
targeted therapy
precision medicine
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
nausea
vomiting
diarrhea
elevated liver enzymes
|
|
gptkbp:status
|
approved
|
|
gptkbp:targets
|
gptkb:NTRK_gene_fusions
|
|
gptkbp:type
|
gptkb:Atom
|
|
gptkbp:used_for
|
treatment of cancer
|
|
gptkbp:bfsParent
|
gptkb:LOXO
|
|
gptkbp:bfsLayer
|
6
|